Sydney University researchers to get $1.12 million for vaccine testing
Category: #health  By Saipriya Iyer  Date: 2020-11-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sydney University researchers to get $1.12 million for vaccine testing

Researchers at the University of Sydney have reportedly been rewarded over $1.12 million as funding from the IMCRC (Innovative Manufacturing CRC) to conduct independent clinical research tests to assess the efficacy of needle-free vaccination for at-risk individuals. The $1.12 million grant reflects the matched funding the university received from the Commonwealth Government funded IMCRC and Australian biotech firm, Vaxxas.

The two new clinical trials are specifically designed to assess the usability, acceptability, feasibility, and safety of Vaxxas’ vaccine delivery technology’s self-administration through an inactive substance. Both studies would aim at healthcare professionals and older adults who are prone to be severely affected by SARS-COV-2 and influenza.

Professor Rachel Skinner, lead researcher, Faculty of Medicine and Health at the University of Sydney, as well as Kids Research at Sydney Children’s Hospital Network, stated that the device offers potential benefits in comparison to vaccination given using a syringe and needle based administration method.

The aim is for the device to need only a small dose of vaccine to create a similar immune response level in the recipient. Additionally, there is no need to refrigerate the device, which makes it easier and cheaper to store and transport. It is also developed to be easy to use, with the ability to be self-administered, added Skinner.

The said device is a biocompatible polymer of one square centimeter, which is smaller than a typical postage stamp, covered in thousands of micro-projections that cannot be seen with a naked eye. These micro-projections are covered with a vaccine formulation and designed to pierce the outer protective layer of the skin to deliver the vaccine to the cell layers that are present immediately below the skin, which is rich in immune cells.

A disposable applicator which contains the product is used to apply the device on the skin. However, this vaccine technology is currently still being developed and has not been authorized for use.

Source credit: https://www.sydney.edu.au/news-opinion/news/2020/11/23/sydney-to-undertake-clinical-studies-of-needle-free-vaccine-patc0.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

EU starts mass COVID-19 vaccination program in 27 member-states
EU starts mass COVID-19 vaccination program in 27 member-states
By Saipriya Iyer

The European Union has recently started a mass COVID-19 vaccination campaign to inoculate over 450 million individuals in 27 member-states.

EU leaders have reportedly negotiated var...

Asus announces plans to strengthen its offline retail presence in India
Asus announces plans to strengthen its offline retail presence in India
By Saipriya Iyer

AsusTek Computer Inc., popularly known as Asus, has reportedly announced plans to strengthen its offline retail presence across India. The firm, which had 7.5% of total market share in the Indian PC segment in the Q3 o...

Need for efficient sea vessels to augment marine turbocharger deployment
Need for efficient sea vessels to augment marine turbocharger deployment
By Saipriya Iyer

Increasing globalization and the subsequent rise in seaborne trade activities are fueling the global marine turbochargers industry size. These trends have created a significant demand for commercial vessels. Growth of ...